Importantly, we demonstrate that in selected patient-derived breast cancer xenograft (PDX) models, GANT61 (a GLI1/2 inhibitor) inhibits tumour growth, whereas IPI926 (a SMO inhibitor) does not. Here, SMO is linked to breast carcinoma.